Novartis said its Phase III HARBOR study of del-desiran in myotonic dystrophy
type 1 (DM1) failed to meet the primary endpoint; video hand-opening time (vHOT)
showed no statistically significant improvement versus placebo. The company
reported signals of clinical activity in secondary and exploratory analyses and
said safety was overall consistent with prior data. Novartis will analyze the
full dataset and consult regulators to determine next steps.
